FDA Center for Drug Evaluation & Research Issues Warning Letter to Terramed
October 07, 2026
October 07, 2026
WASHINGTON, Oct. 7 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Terramed from its Center for Drug Evaluation and Research:
* * *
Recipient: Krystsina Uradzimskaya, CEO, Terramed, 10731 Queen Ave, La Mesa, CA 91941, United States, support@terramed.info, info@puritycosmetics.com
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
9310 Towne Cente . . .
* * *
Recipient: Krystsina Uradzimskaya, CEO, Terramed, 10731 Queen Ave, La Mesa, CA 91941, United States, support@terramed.info, info@puritycosmetics.com
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
9310 Towne Cente . . .